Bioresorbable vascular scaffold (BRS/bioabsorbable stents are a new and promising generation of intravascular devices that may potentially circumvent many of the problems associated with permanent metallic stents for coronary artery bypass graft surgery. The ABSORB™ BRS (Abbott Vascular, Santa Clara, California, USA) received Conformité Européenne (CE) mark approval in 2011 and has been implanted in over 150,000 patients over the globe.
In this issue
Rate this content's potential impact on patient outcomes
Thank you!
Please share some more information on the rating you have given